A Case Of Venetoclax Combined With Azacitidine In The Treatment Of Chronic Lymphocytic Leukemia Treat Related Acute Myeloid Leukemia And Literature Review

Objective: To summarize the clinical characteristics,diagnosis,treatment and,related progress of the therapy related acute myeloid leukemia,and to target the BCL-2 inhibitor Venetoclax and azacitidine in the treatment of chronic lymphocytic leukemia and acute myeloid leukemia.Thestatus of treatment,specific analysis of the curative effect evaluation and,related progress of venetoclax and azacitidine in the treatment of leukemia.Methods:A retrospective analysis of a patient with acute myeloid leukemia related to the treatment of chronic lymphocytic leukemia treated with Venetoclax combine with azacitidine and a review of related literature.Results: A 78-year-old female was admitted to the hospital for the first time on November 26,2013,mainly due to dizziness and fatigue for 5 days.According to blood routine,bone marrow cytology,bone marrow pathology,chromosome karyotype analysis,bone marrow flow cytometry and other examinations,he was diagnosed with chronic lymphocytic leukemia.He was given chlorambucil 2 mg orally 2/day to treat the primary disease.Later,the patient was diagnosed with chronic lymphocytic leukemia for more than 6years and 6 months,and was admitted to the hospital for the second time on July 17,2020 for fatigue and 3 months.Acute myeloid leukemia was diagnosed based on bone marrow cytology,flow cytometry,fusion genes and next-generation sequencing,and supportive treatment such as infection control and blood transfusion products was given.Azacitidine combined with Venetoclax has been applied for 4 courses of treatment.Evaluation reached complete remission.Conclusions:Therapy related acute myeloid leukemia usually occurs after the application of alkylating agents,topoisomerase II,taxanes and other tumorous hematopoietic diseases.Most patients have a worse prognosis and shorter survival time than primary acute myeloid leukemia.However,elderly patients with acute myeloid leukemia have not yet found a clear treatment plan due to poor prognosis and many underlying diseases,which are not suitable for strong chemotherapy and treatment resistance.Combining the bcl-2 inhibitor venetoclax with the demethylating drug azacitidine in the treatment of chronic lymphocytic leukemia treat related acute myeloid leukemia can relieve the patient and provide a new reference for the treatment of such diseases in the future.